<DOC>
	<DOCNO>NCT02653625</DOCNO>
	<brief_summary>This single-arm , open label , proof concept ( PoC ) study Cenicriviroc ( CVC ) adult subject Primary Sclerosing Cholangitis ( PSC ) . The main objective PoC study ass change alkaline phosphatase ( ALP ) individually group , 24 week treatment CVC .</brief_summary>
	<brief_title>PERSEUS : Preliminary Efficacy Safety Cenicriviroc Adult Subjects With Primary Sclerosing Cholangitis</brief_title>
	<detailed_description />
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis , Sclerosing</mesh_term>
	<mesh_term>TAK-652</mesh_term>
	<criteria>Subjects chronic cholestatic liver disease least 6 month Clinical diagnosis PSC evident chronic cholestasis six month duration either consistent magnetic resonance cholangiopancreatography ( MRCP ) /endoscopic retrograde cholangiopancreatography ( ERCP ) show sclerosing cholangitis , liver biopsy take time consistent PSC absence document alternative etiology sclerosing cholangitis . If diagnosis PSC make histology alone , must require presence fibroobliterative lesion ( ie , onion skin lesion ) Documented evidence Inflammatory Bowel Disease ( IBD ) either prior endoscopy previous medical record , &gt; = 6 month . In addition , subject require enter study Partial Mayo Risk score 03 , inclusively In subject receive treatment ursodeoxycholic acid ( UDCA ) , therapy must stable least 3 month , dose great 20 mg/kg/day Serum ALP great 1.5 × upper limit normal ( ULN ) Ability understand sign write informed consent form ( ICF ) Subjects receive allow concomitant medication need stable therapy 28 day prior Baseline Visit Presence document secondary sclerosing cholangitis ( ischemic cholangitis , recurrent pancreatitis , intraductal stone disease , severe bacterial cholangitis , surgical blunt abdominal trauma , recurrent pyogenic cholangitis , choledocholithiasis , toxic slerosing cholangitis due chemical agent , cause secondary sclerosing cholangitis ) prior clinical investigation Small duct PSC Presence percutaneous drain bile duct stent History cholangiocarcinoma high clinical suspicion dominant stricture within 1 year MRCP/ERCP clinical judgment Ascending cholangitis within 60 day prior Screening Alcohol consumption great 21 units/week male 14 units/week female ( one unit alcohol ½ pint beer [ 285 mL ] , 1 glass spirit [ 25 mL ] 1 glass wine [ 125 mL ] ) Prior plan liver transplantation Presence alternative cause chronic liver disease , include alcoholic liver disease , nonalcoholic steatohepatitis , primary biliary cirrhosis , autoimmune hepatitis History cirrhosis and/or hepatic impairment ( ChildPugh class A , B C ) and/or hepatic decompensation include ascites , encephalopathy variceal bleeding . Subjects show evidence significant worsen hepatic function exclude Subjects fibrosis evidence cirrhosis , determine local transient elastography ( TE , e.g. , Fibroscan ) value &gt; = 13.0 kPa , take within last 6 month . If TE conduct within 6 month prior screen one conducted screening period use Baseline value . Moderate Severe active IBD flare colitis activity within last 90 day require intensification therapy beyond Baseline treatment . Subjects stable mild moderate IBD , treatment , allow provide stable 3 month 5amino salicylic acid drug Azathioprine ( allow dose azathioprine 50200 mg/day ) Use oral prednisolone &gt; 10 mg/day , biologics and/or hospitalization colitis within 90 day disallow Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ; allow cutoff , determine mean Screening preBaseline value ( subject show evidence significant worsen liver transaminases repeat measure exclude ) : AST &gt; 200 IU/L male females ALT : male &gt; 250 IU/L female &gt; 200 IU/L Total Bilirubin Direct Bilirubin ; allow cutoff , determine mean Screening preBaseline value ( subject show evidence significant worsen bilirubin exclude ) : Total Bilirubin ≥ 1.5 mg/dL Direct Bilirubin ≥ 0.5 mg/dL International normalized ratio &gt; 1.3 absence anticoagulant Immunoglobulin G4 ( IgG4 ) &gt; 4 × ULN Screening evidence IgG4related sclerosing cholangitiss Females pregnant breastfeed Any clinically significant disorder prior therapy , opinion investigator , would make subject unsuitable study unable comply dose protocol requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Primary Sclerosing Cholangitis</keyword>
</DOC>